Clinical trials: Dyslipidaemia
Hypercholesterolemia
Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL)
Both simvastatin 40 mg and simvastatin/ezetimibe 10/10 mg result in low-density lipoprotein cholesterol (LDL-C) reductions of approximately the same magnitude.
- Trial name
- NCT00932620
- Testing
- SIMVASTATIN 40 mg, SIMVASTATIN/EZETIMIBE 10/10 mg
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University of Ioannina
Coronary Artery Disease, Coronary Disease
Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI
This study is a prospective, randomized, open-label, single-center trial designed to compare the 30 month-safety and efficacy between low-dose (5mg/dL) and high-dose (20mg/dL) rosuvastatin treatment for patients with coronary…
- Conditions
- Coronary Artery Disease, Coronary Disease, Cardiovascular Diseases
- Trial name
- ROSUVA-30 (NCT02859480)
- Testing
- Rosuvastatin 5mg, Rosuvastatin 20mg
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Korea University Anam Hospital
Coronary Artery Disease, Arterial Stiffness, Blood Pressure
Expanded Studies on the SCAPIS Stockholm Reexamination Cohort
The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018.
- Conditions
- Coronary Artery Disease, Arterial Stiffness, Blood Pressure, AORTIC VALVE DISEASES, Mitral Valve Stenosis and/or Insufficiency
- Trial name
- SCAPIS-ReEx (NCT07476703)
- Testing
- Coronary computer tomography (CCTA), Echocardiograhy and aortic ultrasound, Liver elastography
- Where
- Sweden
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- Danderyd Hospital
Hyperlipidemias
L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release
The gut is able to retain some fat for many hours after a fatty meal. The gut hormone glucagon-like peptide-2 (GLP-2) is known to release these fat stores in the gut, but it is not known how GLP-2 achieves this.
- Trial name
- LNMMA (NCT03534661)
- Testing
- Teduglutide + Normal Saline, Teduglutide + L-NMMA
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
NAFLD, Obesity
Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD)
Epidemiological data and studies in animal models suggest, that polyunsatured fatty acids (PUFA) rather than mono-unsatured fatty acids (MUFA) are associated with lower hepatic lipid content (HCL) and may facilitate a decrease of…
- Conditions
- NAFLD, Obesity, Prediabetes, Dyslipoproteinemia
- Trial name
- UFOP-2 (NCT02458586)
- Testing
- Dietary intervention / counseling
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- German Institute of Human Nutrition
Metabolic Syndrome, Overweight and Obesity
The Soy Treatment Evaluation for Metabolic Health (STEM) Trial
Strategies to reduce sugar-sweetened beverages (SSB) have become one of the leading public health targets to address the epidemics of obesity and diabetes.
- Conditions
- Metabolic Syndrome, Overweight and Obesity, PreDiabetes, Diabetes
- Trial name
- NCT05191160
- Testing
- Soy Milk, Cow's Milk, Sugar Sweetened Beverages
- Where
- Canada
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Hypercholesterolemia
Differential Metabolic Effects of Statins
The investigators hypothesized simvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients.
- Trial name
- NCT00546559
- Testing
- statins (simvastatin, pravastatin)
- Where
- South Korea
- Sponsor
- Gachon University Gil Medical Center
Nutrition, Healthy, Dyslipidemia
Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose
Cardiovascular disease risk factors, including higher BMIs and poor cholesterol profiles, are on the rise and contribute to the United States' growing disease burden.
- Conditions
- Nutrition, Healthy, Dyslipidemia, Overweight and Obesity
- Trial name
- NCT07696403
- Testing
- Pecan, Control
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of Georgia
Hyperlipidemia, Diabetes
Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness
The study was a 12-month, multi-centered, quasi-experimental design to assess point-of-care (POCT) screening/monitoring of subjects on antipsychotic agents for metabolic syndrome.
- Conditions
- Hyperlipidemia, Diabetes, Hypertension
- Trial name
- NCT02029989
- Testing
- Glucose and lipids, Glycosylated Hemoglobin A1c, Blood Pressure and Heart Rate
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Dyslipidemias, Hypercholesterolemia
Effect of Statins on Lipid Levels Following the First Acute Coronary Event (MK-0000-204)
The current study is proposed to investigate the pattern of dyslipidemia and of lipid treatment practices in patients in India experiencing their first acute cardiovascular event and the extent of residual dyslipidemia after 12…
- Conditions
- Dyslipidemias, Hypercholesterolemia, Hypertriglyceridemia, High LDL-C
- Trial name
- REMAINS (NCT01245738)
- Volunteers
- 635 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Hyperglycemia
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
The objective of this study is to pilot a multifaceted, optimized intervention for metabolic syndrome (MetS) in emergency department patients to establish feasibility.
- Conditions
- Hypertension, Hyperglycemia, Dyslipidemia, Metabolic Syndrome
- Trial name
- METS (NCT07119658)
- Testing
- Composite intervention to address MetS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Indiana University
Obesity, Hypercholesterolemia
Plant-Based, American Heart Assoc. or Mediterranean Diets In 9-18 yo With BMI >95%, Cholesterol >169 and Their Parents
The purpose of this research is to investigate the effects of a PB no- added-fat and the AHA and MED in obese (BMI >95%) children ages 9-18 with hypercholesterolemia (>169 mg/dl) and a parent or guardian.
- Conditions
- Obesity, Hypercholesterolemia, Cardiovascular Disease
- Trial name
- NCT02857543
- Testing
- Plant-Based Diet, American Heart Association Diet, Mediterranean Diet
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- The Cleveland Clinic
Dyslipidemia
A Clinical Study to Evaluate the Effect of Mobile Applications "My A:Care" and "Smart Coach" on the Lipid-lowering Treatment Adherence of Subjects With Dyslipidemia in Thailand
A prospective, randomized, open-label, clinical study to evaluate the effect of mobile applications "My A:Care" and "Smart Coach" on the lipid-lowering treatment adherence of subjects with dyslipidemia in Thailand
- Trial name
- My A:Care (NCT05370703)
- Testing
- My A:care, Smart Coach
- Where
- Thailand
- Volunteers
- 150 people
- Sponsor
- Abbott
PFAS, Environmental Exposures
Use of Bile Acid Binding Resins to Decrease PFAS Levels Via Colesevalem in Veterans Study
The goal of this study is to test the efficacy and feasibility of Colesevelam administration (50% of the recommended dose) to reduce serum PFAS concentration in the Veteran population who have serum PFAS levels that exceed the…
- Conditions
- PFAS, Environmental Exposures, Occupational Exposure to Chemicals, Military Exposure
- Trial name
- PAVERS (NCT07592858)
- Testing
- Colesevelam
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Rhode Island
Dyslipidemia
Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study
The investigators propose to investigate if using a combination of medications that may improve cholesterol give additional benefit to that gained from the statin medication, Lipitor.
- Trial name
- CENTAUR (NCT00728910)
- Testing
- Atorvastatin, ABT335, ER Niacin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pennsylvania
Cardiovascular Disease, Hyperlipidemia
Effect of Evolocumab on Coronary Atherosclerosis
This study will quantify changes in coronary plaque volumes and plaque composition in patients treated with evolocumab. Previous intravascular ultrasound studies have shown that treatment with a lipid-lowering PCSK9 enzyme…
- Trial name
- NCT03689946
- Testing
- Evolocumab, 18F-NaF PET, CCTA
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Cedars-Sinai Medical Center
Hyperlipidemia
A Extension Study to Evaluate the Safety and Efficacy of HRS-7249 in Patients With Hypertriglyceridemia
This is a Phase II multi-center, open-label extension (OLE) clinical trial of HRS-7249, a GalNAc-conjugated APOC3-targeted siRNA injection, enrolling two cohorts of participants.
- Trial name
- NCT07799688
- Testing
- HRS-7249 Injection
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Metabolic X Syndrome Dyslipidemia
MK0767 in Metabolic Syndrome-Dyslipidemia (0767-016)
This is a clinical trial in patients with Metabolic Syndrome and Dyslipidemia to study the effects of MK0767 on triglycerides.
- Trial name
- NCT00703690
- Testing
- MK0767, Comparator: fenofibrate
- Volunteers
- 436 people
- Sponsor
- Merck Sharp & Dohme LLC
Familial Hypercholesterolemia
Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)
Diagnosis rates of familial hypercholesterolemia (FH) are low in the United States, despite multiple guidelines and recommendations for screening and treatment of high cholesterol, to prevent heart attacks in those affected.
- Trial name
- CARE-FH (NCT05284513)
- Testing
- FH diagnosis program, Implementation strategy package: Develop and implement tools for quality monitoring, Implementation strategy package: Develop educational materials
- Where
- United States
- Volunteers
- 532 people
- Sponsor
- Geisinger Clinic
Healthy, Hypercholesterolemia
Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase
This is a Phase 1, open-label, single-dose, randomized, dose escalation study in healthy and hypercholesterolemic subjects. Each subject will receive 1 of 5 treatments as a single subcutaneous injection.
- Trial name
- NCT02667223
- Testing
- Cohort 1: bococizumab 150 mg + rHuPH20, Cohort 2: bococizumab 300 mg, Cohort 3: bococizumab 300 mg + rHuPH20
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pfizer